Watson Pharmaceuticals (Actavis Inc.) / Amarin Development AB (Amarin Corp subsidiary)

Type 2 Diabetes Mellitus (Glipizide ER + oral controlled-release platform)

$1.2B Global glipizide market 2024

Disease Overview

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell failure, affecting more than 38 million Americans. Sulfonylureas like glipizide stimulate pancreatic insulin secretion and remain a low-cost second- or third-line oral therapy, typically used after metformin.

Competitive Landscape

In 2003, the oral diabetes market was dominated by Pfizer's branded Glucotrol XL (glipizide ER), Bristol-Myers Squibb's Glucophage (metformin), and the emerging thiazolidinedione class (Avandia, Actos). Watson's acquisition of Amarin Development AB (ADAB) in October 2003 brought in-house the proprietary oral controlled-release drug-delivery platform that ADAB had used to develop a generic glipizide extended-release formulation, plus pipeline reformulations. Watson received FDA approval for Glipizide ER 5mg in September 2003 and 10mg in November 2003 (BioSpace), giving it first-mover position in the AB-rated generic Glucotrol XL market. The deal mattered strategically because it converted Watson from a buyer of formulation IP into an owner of a Swedish R&D site capable of generating future controlled-release ANDAs across cardiovascular, CNS, and metabolic generics. Subsequent commodification of glipizide and the rise of DPP-4 inhibitors (Januvia, 2006), GLP-1s and SGLT2s have since marginalized sulfonylurea share, but the platform underpinned Watson's broader controlled-release generics franchise that ultimately contributed to the Actavis combination.